A Randomized, Phase III Study of Lenvatinib in Chinese Patients with Radioiodine-Refractory Differentiated Thyroid Cancer.

Xiangqian ZhengZhengang XuQinghai JiMinghua GeFeng ShiJianwu QinFeng WangGuang ChenYuan ZhangRui HuangJian TanTao HuangSijin LiZhongwei LvYansong LinZhuming GuoTomoki KubotaTakuya SuzukiHiroki IkezawaMing Gao

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)

Lenvatinib at a starting dose of 24 mg/day significantly improved progression-free survival and objective response rate in Chinese patients with RR-DTC versus placebo. There were no new or unexpected toxicities. Results are consistent with those from SELECT involving patients with RR-DTC.

Keyphrases

phase iii
free survival
open label
clinical trial
double blind
placebo controlled
phase ii
randomized controlled trial
study protocol